"Atrial fibrillation and ischemic stroke"@en . "Atrial fibrillation is the cause of every second cardioembolic stroke and is responsible for approximately 10 to 15% of all ischemic strokes. Almost 40% of strokes in the age group above years are caused by atrial fibrillation and will become even more serious health burden with projected population aging. The cardioembolic strokes compared to the other stroke subtypes are the most serious - with the most severe neurologic deficit on admission, the highest 90 days mortality and the worst clinical outcome. About 70% of strokes in atrial fibrillation patients are caused by cardioembolic mechanism. This article provides the reader with an overview of perspective diagnostic methods in stroke patients with atrial fibrillation -duration of ECG monitoring, biomarkers (D-dimer, BNP) and transcranial doppler sonography. The most effective strategy in the secondary prevention of cardioembolic stroke is anticoagulation despite the higher risk of intracranial bleeding. Additional clinical parameters suitable for further bleeding risk assessment, such as cerebral microbleeds and warfarin pharmacogenetics, that could complement HAS-BLED score and timing of anticoagulation initiation are discussed."@en . "[D1A923DECBF3]" . "CZ - \u010Cesk\u00E1 republika" . "Fibrilace s\u00EDn\u00ED zp\u016Fsobuje zhruba ka\u017Edou druhou kardioembolickou ischemickou c\u00E9vn\u00ED mozkovou p\u0159\u00EDhodu a je tak p\u0159\u00ED\u010Dinou asi 10 a\u017E 15 % v\u0161ech ischemick\u00FDch c\u00E9vn\u00EDch mozkov\u00FDch p\u0159\u00EDhod. V populaci nad 80 let v\u011Bku p\u0159edstavuj\u00ED kardioembolick\u00E9 ischemick\u00E9 c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody a\u017E 40 % v\u0161ech ischemick\u00FDch c\u00E9vn\u00EDch mozkov\u00FDch p\u0159\u00EDhod a vzhledem ke st\u00E1rnut\u00ED populace budou p\u0159edstavovat nar\u016Fstaj\u00EDc\u00ED z\u00E1t\u011B\u017E. Ischemick\u00E9 c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody u pacient\u016F s fibrilac\u00ED s\u00EDn\u00ED maj\u00ED ve srovn\u00E1n\u00ED ostatn\u00EDmi subtypy ikt\u016F nejt\u011B\u017E\u0161\u00ED vstupn\u00ED neurologick\u00FD deficit, nejvy\u0161\u0161\u00ED 90denn\u00ED mortalitu a nejhor\u0161\u00ED v\u00FDsledn\u00FD stav pacient\u016F. Zhruba 70 % v\u0161ech ischemick\u00FDch c\u00E9vn\u00EDch mozkov\u00FDch p\u0159\u00EDhod u pacient\u016F s fibrilac\u00ED s\u00EDn\u00ED je zp\u016Fsobeno kardioemboliza\u010Dn\u00EDm mechanismem. Diagnostiku etiologie ischemick\u00E9 c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody nelze prov\u00E9st pouze na z\u00E1klad\u011B klinick\u00E9ho vy\u0161et\u0159en\u00ED. V \u010Dl\u00E1nku jsou diskutov\u00E1ny specifick\u00E9 ot\u00E1zky diagnostiky ischemick\u00E9 c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody u t\u011Bchto pacient\u016F - d\u00E9lka monitorace rytmu, vyu\u017Eit\u00ED biomarker\u016F (D-dimer, BNP) a transkrani\u00E1ln\u00ED dopplerovsk\u00E9 sonografie. Nejp\u0159\u00EDnosn\u011Bj\u0161\u00ED strategi\u00ED v sekund\u00E1rn\u00ED prevenci ischemick\u00E9 c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody u pacient\u016F s fibrilac\u00ED s\u00EDn\u00ED je antikoagula\u010Dn\u00ED l\u00E9\u010Dba, jej\u00ED rizika jsou v\u0161ak nejv\u00FDznamn\u011Bj\u0161\u00ED pr\u00E1v\u011B pro pacienty po mozkov\u00E9 p\u0159\u00EDhod\u011B. D\u00E1le jsou diskutov\u00E1ny dopl\u0148uj\u00EDc\u00ED parametry umo\u017E\u0148uj\u00EDc\u00ED zp\u0159esnit z\u00E1kladn\u00ED odhad rizika krv\u00E1civ\u00FDch komplikac\u00ED (nap\u0159. vyu\u017Eit\u00EDm HAS-BLED sk\u00F3re), jako jsou cerebr\u00E1ln\u00ED mikrohemoragie nebo farmakogenetika warfarinu a ot\u00E1zka \u010Dasov\u00E1n\u00ED zah\u00E1jen\u00ED antikoagulace po iktu." . . "Fibrilace s\u00EDn\u00ED a c\u00E9vn\u00ED mozkov\u00E1 p\u0159\u00EDhoda."@cs . "13" . . . "Fibrilace s\u00EDn\u00ED a c\u00E9vn\u00ED mozkov\u00E1 p\u0159\u00EDhoda." . "Atrial fibrillation"@en . . . "Fibrilace s\u00EDn\u00ED a c\u00E9vn\u00ED mozkov\u00E1 p\u0159\u00EDhoda." . "RIV/00064203:_____/11:7909!RIV12-MZ0-00064203" . "P\u0159\u00EDloha 1" . . . "1"^^ . "1212-4184" . "1"^^ . "Fibrilace s\u00EDn\u00ED zp\u016Fsobuje zhruba ka\u017Edou druhou kardioembolickou ischemickou c\u00E9vn\u00ED mozkovou p\u0159\u00EDhodu a je tak p\u0159\u00ED\u010Dinou asi 10 a\u017E 15 % v\u0161ech ischemick\u00FDch c\u00E9vn\u00EDch mozkov\u00FDch p\u0159\u00EDhod. V populaci nad 80 let v\u011Bku p\u0159edstavuj\u00ED kardioembolick\u00E9 ischemick\u00E9 c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody a\u017E 40 % v\u0161ech ischemick\u00FDch c\u00E9vn\u00EDch mozkov\u00FDch p\u0159\u00EDhod a vzhledem ke st\u00E1rnut\u00ED populace budou p\u0159edstavovat nar\u016Fstaj\u00EDc\u00ED z\u00E1t\u011B\u017E. Ischemick\u00E9 c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody u pacient\u016F s fibrilac\u00ED s\u00EDn\u00ED maj\u00ED ve srovn\u00E1n\u00ED ostatn\u00EDmi subtypy ikt\u016F nejt\u011B\u017E\u0161\u00ED vstupn\u00ED neurologick\u00FD deficit, nejvy\u0161\u0161\u00ED 90denn\u00ED mortalitu a nejhor\u0161\u00ED v\u00FDsledn\u00FD stav pacient\u016F. Zhruba 70 % v\u0161ech ischemick\u00FDch c\u00E9vn\u00EDch mozkov\u00FDch p\u0159\u00EDhod u pacient\u016F s fibrilac\u00ED s\u00EDn\u00ED je zp\u016Fsobeno kardioemboliza\u010Dn\u00EDm mechanismem. Diagnostiku etiologie ischemick\u00E9 c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody nelze prov\u00E9st pouze na z\u00E1klad\u011B klinick\u00E9ho vy\u0161et\u0159en\u00ED. V \u010Dl\u00E1nku jsou diskutov\u00E1ny specifick\u00E9 ot\u00E1zky diagnostiky ischemick\u00E9 c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody u t\u011Bchto pacient\u016F - d\u00E9lka monitorace rytmu, vyu\u017Eit\u00ED biomarker\u016F (D-dimer, BNP) a transkrani\u00E1ln\u00ED dopplerovsk\u00E9 sonografie. Nejp\u0159\u00EDnosn\u011Bj\u0161\u00ED strategi\u00ED v sekund\u00E1rn\u00ED prevenci ischemick\u00E9 c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody u pacient\u016F s fibrilac\u00ED s\u00EDn\u00ED je antikoagula\u010Dn\u00ED l\u00E9\u010Dba, jej\u00ED rizika jsou v\u0161ak nejv\u00FDznamn\u011Bj\u0161\u00ED pr\u00E1v\u011B pro pacienty po mozkov\u00E9 p\u0159\u00EDhod\u011B. D\u00E1le jsou diskutov\u00E1ny dopl\u0148uj\u00EDc\u00ED parametry umo\u017E\u0148uj\u00EDc\u00ED zp\u0159esnit z\u00E1kladn\u00ED odhad rizika krv\u00E1civ\u00FDch komplikac\u00ED (nap\u0159. vyu\u017Eit\u00EDm HAS-BLED sk\u00F3re), jako jsou cerebr\u00E1ln\u00ED mikrohemoragie nebo farmakogenetika warfarinu a ot\u00E1zka \u010Dasov\u00E1n\u00ED zah\u00E1jen\u00ED antikoagulace po iktu."@cs . . "Postgradu\u00E1ln\u00ED medic\u00EDna" . "I" . "http://www.medvik.cz/link/bmc11022122" . . "Tomek, Ale\u0161" . . . "Fibrilace s\u00EDn\u00ED a c\u00E9vn\u00ED mozkov\u00E1 p\u0159\u00EDhoda."@cs . . "199590" . . "Atrial fibrillation and ischemic stroke"@en . "RIV/00064203:_____/11:7909" . "6"^^ .